Literature DB >> 20045287

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.

Zhi-Dong Jiang1, Shi Ke, Herbert L Dupont.   

Abstract

Rifaximin shortens the duration of travellers' diarrhoea without important alteration of colonic flora. This study investigated the expression of virulence factors [heat-stable (ST) and heat-labile (LT) enterotoxins, surface adhesion factors (CS2/CS3, CS6) and matrix metalloproteinase-9 (MMP-9)] as well as the interleukin (IL)-8 induction potential of diarrhoeagenic Escherichia coli and Shigella sonnei strains exposed to rifaximin (8, 32 and 64mg/L) for 4, 8, 18 and 24h. Following exposure to rifaximin, enterotoxigenic E. coli (ETEC) isolates did not express ST/LT, CS2/CS3 or CS6, whereas enteroaggregative E. coli (EAEC) and S. sonnei isolates did not produce detectable amounts of MMP-9. Moreover, induction of IL-8 was undetectable. At subinhibitory concentrations, rifaximin alters the virulence of ETEC, EAEC and S. sonnei isolates. These findings help explain the efficacy of rifaximin despite minimal alteration of colonic flora. Copyright 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045287     DOI: 10.1016/j.ijantimicag.2009.11.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  24 in total

1.  Treatment options for covert hepatic encephalopathy.

Authors:  Nisheet Waghray; Abhijeet Waghray; Kevin Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

Review 2.  The role of microbiota in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Gut Microbes       Date:  2014-04-01

3.  Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

Authors:  Qiang Zhu; Li Zou; Kumaravelu Jagavelu; Douglas A Simonetto; Robert C Huebert; Zhi-Dong Jiang; Herbert L DuPont; Vijay H Shah
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

Review 4.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

5.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

Authors:  Genta Kakiyama; William M Pandak; Patrick M Gillevet; Phillip B Hylemon; Douglas M Heuman; Kalyani Daita; Hajime Takei; Akina Muto; Hiroshi Nittono; Jason M Ridlon; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Leroy R Thacker; Masoumeh Sikaroodi; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2013-01-16       Impact factor: 25.083

6.  Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation.

Authors:  D Weber; P J Oefner; K Dettmer; A Hiergeist; J Koestler; A Gessner; M Weber; F Stämmler; J Hahn; D Wolff; W Herr; E Holler
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

7.  Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis.

Authors:  Nolan Faust; Akihiro Yamada; Haider Haider; Yuga Komaki; Fukiko Komaki; Dejan Micic; Atsushi Sakuraba
Journal:  World J Hepatol       Date:  2020-05-27

Review 8.  Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations.

Authors:  David R Tribble
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

9.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

Review 10.  Rifaximin therapy of irritable bowel syndrome.

Authors:  Hoonmo L Koo; Saman Sabounchi; David B Huang; Herbert L DuPont
Journal:  Clin Med Insights Gastroenterol       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.